Login
Home / WINT : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Windtree Therapeutics, Inc.

$0 -$0.03 (-99.33%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$0
Day Range
$0$0.01
Year Range
$0$0.19
Market Cap
6.74K
AVG Volume
106.86K
Trailing/Forward PE
-0/-
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
2026-11-26
Primary Exchange
Other OTCUS
Revenue (USD)
025K50K75K100K23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Net Income (USD)
-30M-20M-10M010M20M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Operating Income (USD)
-20M-15M-10M-5M023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
EBITDA (USD)
-40M-20M020M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Cash Flows (USD)
-8M-6M-4M-2M023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
EPS (USD)
-2000-100001000200023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Expenses (USD)
05M10M15MR&DSG&ACapex23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Cash & Debt (USD)
05M10M15M20MCashLong Term DebtShort Term Debt23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Debt ratios
-0.75-0.5-0.2500.250.523 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Margins
-20000%-15000%-10000%-5000%0%5000%17 Q317 Q418 Q118 Q218 Q318 Q419 Q119 Q220 Q424 Q4
Return on Capital
-400%-200%0%200%400%23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Shares Outstanding
0100K200K300K23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Book Value Per Share (USD)
-1000010002000300023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Total Assets (USD)
020M40M60M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
Employee Count
02040602015201620172018201920202021202220232024
Free Cash Flow Yield
-600000000%-400000000%-200000000%0%med -1810110.25%Jan 25May 25Sep 25Jan 26May 26Sep 26
Price to Sales
01234med 0.01Dec 21Mar 22Jul 25Oct 25Feb 26May 26Sep 26
Price to Book
00.511.52med 0.08Feb 24Jun 24Sep 24Jan 25Apr 25Aug 25Nov 25
Windtree Therapeutics, Inc.
WINT
Stockpicker

Video analysis: WINT

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: WINT

TransCode Therapeutics Announces Leadership Transition

prnewswire.com · 10 Sep 2026

TransCode Therapeutics Announces Leadership Transition

Tom Fitzgerald, Chief Financial Officer, Announces his Retirement John Tattory, to become Interim Chief Financial Officer BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.